dual agonist glp-1 glucagon Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review Tirzepatide, a dual GIP/GLP-1 receptor
Description
Overall, indirect comparisons suggest that SGLT2 inhibitors may offer greater preservation of eGFR than GLP-1 receptor agonists in a broader population of people with type 2 diabetes mellitus and CKD
This product is not recommended for children below 18 years old or pregnant or breastfeeding women
Weeks 8-12+: Sustained metabolic improvements
Disease areas Products Careers About us Patient help Healthcare professionals Media & Investors Contact us
